Hemostasis analyzers market seen reaching $5.66 billion by 2030

The Business Research Company says the global hemostasis analyzers market will grow from $4.05 billion in 2025 to $5.66 billion by 2030 as demand rises for faster, more accurate coagulation testing. North America led the market in 2025, while point-of-care devices and automated analyzers are emerging as key growth areas.

Why it matters: - Hemostasis analyzers are used to measure clotting and help diagnose and manage bleeding disorders. - Rising demand for faster coagulation testing could affect hospitals, clinical laboratories and diagnostic suppliers. - Growth in surgical procedures, cardiovascular disease and aging populations is expanding the need for blood-clotting diagnostics.

What happened: - The Business Research Company published a 2026 market report on the global hemostasis analyzers market. - The report puts the market at $4.05 billion in 2025 and projects $4.34 billion in 2026. - The market is forecast to reach $5.66 billion by 2030. - The report is available as a free sample and as a full market report on The Business Research Company website. - The report includes new analytical features such as market attractiveness scoring, total addressable market analysis, company scoring matrix graphics, Excel forecasting dashboards, market hotspots infographics and updated charts. - The report also points to a LinkedIn page for The Business Research Company and includes contact details for sales and media follow-up.

The details: - The market is expected to grow at a 7.2% CAGR in 2026 and a 6.8% CAGR through 2030. - The report links growth to bleeding and clotting disorders, more hospital-based diagnostic testing, centralized clinical laboratories, surgical volume and wider use of standard coagulation assays. - The forecast also cites advances in optical and electrochemical testing methods, point-of-care diagnostics, an aging global population, more cardiovascular disease and higher investment in diagnostic infrastructure. - Key trends include more use of point-of-care coagulation devices, higher demand for automated and semi-automated analyzers, broader use of hemostasis testing in chronic disease management, growing reagent and consumables demand and a stronger focus on accuracy and turnaround time. - North America held the largest market share in 2025. - Western Europe ranked second in 2025. - The report also covers Asia-Pacific, South East Asia, Eastern Europe, South America, the Middle East and Africa. - A free sample of the report is available. - The full report is also available online. - The company's LinkedIn page is listed in the release. - Additional social links in the release include Facebook and X.

Between the lines: - The forecast suggests hemostasis testing is moving from a specialized lab function toward broader use in routine and point-of-care care. - The emphasis on automation and faster turnaround points to pressure on labs to process more tests with less delay. - The regional ranking suggests mature healthcare systems remain the main revenue base, even as emerging markets create longer-term upside. - The report's extra dashboards and scoring tools signal a push to package market intelligence as a decision-making product, not just a data summary.

What's next: - The market is likely to keep expanding as diagnostic infrastructure improves and point-of-care testing spreads. - Demand should stay tied to chronic disease management, surgery volumes and the need for earlier detection of clotting disorders. - The report's contact information and downloadable sample suggest The Business Research Company is using the release to drive report sales and lead generation.

The bottom line: - Hemostasis analyzers are on track for steady global growth, with the market expected to add more than $1.5 billion by 2030.